No Data
After Losing 47% in the Past Year, Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Institutional Owners Must Be Relieved by the Recent Gain
Key Insights Given the large stake in the stock by institutions, Aldeyra Therapeutics' stock price might be vulnerable to their trading decisions 50% of the business is held by the top 12
BTIG Maintains Aldeyra Therapeutics(ALDX.US) With Buy Rating, Maintains Target Price $11
BTIG analyst Thomas Shrader maintains $Aldeyra Therapeutics(ALDX.US)$ with a buy rating, and maintains the target price at $11.According to TipRanks data, the analyst has a success rate of 37.8% and a
Express News | Aldeyra Therapeutics Inc: Clinical Trial Results and Potential New Drug Application Resubmission Expected in Second Half of 2024
Express News | Aldeyra Therapeutics Completes Enrollment in Phase 3 Clinical Trial of Reproxalap in Dry Eye Disease
Aldeyra Therapeutics to Host Investor Roundtable QA
PDF Version Event Scheduled for Thursday, June 20 at 8:00 a.m. ET LEXINGTON, Mass.--(BUSINESS WIRE)--Jun. 12, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company dev
Aldeyra Therapeutics to Participate in the Jefferies Global Healthcare Conference
PDF Version LEXINGTON, Mass.--(BUSINESS WIRE)--May 29, 2024-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company developing innovative therapies for the tre